Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
21 Nov, 2025, 12.19 AM IST
Biocon Biologics expands collaboration with Civica to supply affordable insulin in USBiocon Biologics is expanding its partnership with Civica. This new agreement will bring affordable Insulin Glargine to patients in the Uni...
17 Oct, 2025, 08.27 PM IST
Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...
08 Aug, 2025, 09.42 PM IST
Biocon Biologics gets USFDA nod for diabetes medicationBiocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...
16 Jul, 2025, 11.07 AM IST
Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...
16 Jul, 2025, 09.54 AM IST
USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditionsBiocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor in...
21 May, 2024, 12.12 PM IST
Biocon's growth drivers are in place: 5 reasons it is this week's stock pickImproving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...
03 Oct, 2022, 06.30 AM IST
Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
26 Apr, 2022, 10.37 AM IST
Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
22 Jan, 2022, 04.07 PM IST
Biocon Q3 Results: Net profit rises 11% YoY to Rs 187 croreThe earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...
21 Jan, 2022, 11.16 AM IST
Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...
19 Nov, 2021, 04.12 PM IST
Biocon eyes $30b US insulin market via its biosimilarsWith the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...
25 Oct, 2021, 08.09 AM IST
Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
21 Oct, 2021, 10.30 AM IST
Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...
30 Jul, 2021, 06.49 PM IST
Biocon sees a sweet spot with its affordable insulin in USThe biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...
05 Dec, 2019, 08.22 AM IST
Biocon's biosimilars progressAnalysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in...
29 Apr, 2016, 12.47 PM IST
- Biosimilar products development gets a USFDA norms boost
A biosimilar is a product that is similar to a biologic, which in turn is any drug produced through a biological route rather than chemical...
01 Mar, 2012, 05.21 AM IST